Minoz Ep (Minocycline)

Minocycline, the active ingredient in Minoz Ep, is a tetracycline antibiotic presented as a tablet for oral use. It treats acne vulgaris, skin infections, respiratory tract infections and urinary tract infections in adults and adolescents.

GNH USA supplies Minoz Ep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Minocycline is used to manage bacterial infections affecting the skin, respiratory system and urinary tract.

Acne vulgaris: reduces inflammatory lesions and bacterial colonisation on the skin. Skin infections: treats cellulitis, abscesses and other bacterial skin conditions. Respiratory tract infections: effective against community‑acquired pneumonia and bronchitis caused by susceptible organisms. Urinary tract infections: eradicates susceptible uropathogens in uncomplicated UTIs.

Minocycline may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting: gastrointestinal upset that may occur shortly after dosing. - Diarrhea: loose stools, sometimes with abdominal cramping. - Photosensitivity: increased skin sensitivity to sunlight, leading to sunburn. - Dizziness or vertigo: transient balance disturbances. - Skin pigmentation changes: darkening of skin or nails with prolonged use. - Taste alteration: metallic or altered taste perception.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions requiring immediate medical attention. - Hepatic toxicity: elevated liver enzymes or jaundice. - Severe hypersensitivity: anaphylaxis, angioedema, or serum sickness‑like reactions. - Pseudotumor cerebri: increased intracranial pressure presenting with headache and visual changes. - Autoimmune hemolytic anemia: destruction of red blood cells. - Bone marrow suppression: pancytopenia or aplastic anemia.

Before prescribing Minocycline, clinicians should consider several safety aspects.

Pregnancy and lactation: avoid use unless benefits outweigh potential risks, as safety data are limited. Renal or hepatic impairment: adjust therapy and monitor function closely. Age restrictions: not recommended for children under 8 years due to tooth discoloration risk. Concurrent tetracycline use: avoid combining with other tetracyclines to prevent additive toxicity. Photosensitivity risk: advise patients to use sunscreen and protective clothing. Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Minocycline can interact with several medicines, altering efficacy or safety.

Major Interactions (Avoid): - Isotretinoin: increased risk of intracranial hypertension. - Warfarin: potentiation of anticoagulant effect, requiring INR monitoring. - Oral contraceptives: reduced contraceptive effectiveness.

Moderate Interactions (Monitor Closely): - Antacids or calcium supplements: may decrease Minocycline absorption; separate dosing by at least 2 hours. - Penicillins: potential antagonism reducing antibacterial activity. - Cyclosporine: increased risk of nephrotoxicity; monitor renal function.